CXCR4 and prostate carcinoma: Breast cancer cells home to the same areas of bone that harbour the HSC niche, and using prostate cancer models Shiozawa and colleagues demonstrated that mobilisation HSCs caused by administration of the CXCR4 antagonist AMD3100 in vivo increased the number of prostate cancer able to seed in the bone [20], [21].